Enhanced transdermal drug delivery techniques: An extensive review of patents

Recent Patents on Drug Delivery and Formulation

Volumn 3, Issue 2, 2009, Pages 105-124

  Rizwan, Mohammad ^a   Aqil, Mohammad ^a   Talegaonkar, Sushama ^a   Azeem, Adnan ^a   Sultana, Yasmin ^a   Ali, Asgar ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Electroporation; Iontophoresis; Liposome and microemulsion; Transdermal

Indexed keywords

ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; CALCITONIN; CORTICOSTEROID; DRUG; DRUG CARRIER; ERYTHROPOIETIN; ETHOSOME; GAMMA INTERFERON; GLYCERYL TRINITRATE; INSULIN; ISIS 3082; KETOPROFEN; KETOTIFEN; LIDOCAINE; LIPOSOME; METHOTREXATE; MINOXIDIL; NIOSOME; PENETRATION ENHANCING AGENT; POLYMER; PRILOCAINE; SELEGILINE; SILICON; SOLID LIPID NANOPARTICLE; TESTOSTERONE; TRANSFERSOME; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; NANOPARTICLE; PHARMACEUTICAL VEHICLES AND ADDITIVES;

CHRONIC PAIN; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DOSE RESPONSE; DRUG ADSORPTION; DRUG BLOOD LEVEL; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG RELEASE; DRUG SAFETY; DRUG TRANSPORT; ELECTROOSMOSIS; ELECTROPORATION; HUMAN; IONTOPHORESIS; LIPID VESICLE; LIPOPHILICITY; MAGNETISM; MICROEMULSION; MICROINJECTION; NONHUMAN; PAIN; PHOSPHOLIPID VESICLE; PRIORITY JOURNAL; PULSED ELECTRIC FIELD; REVIEW; SKIN IRRITATION; SKIN PENETRATION; STRATUM CORNEUM; TREMOR; ULTRASOUND; CHEMISTRY; EMULSION; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; PATENT; PERMEABILITY; SKIN; SKIN ABSORPTION;

ADJUVANTS, PHARMACEUTIC; ADMINISTRATION, CUTANEOUS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; ELECTROPORATION; EMULSIONS; HUMANS; IONTOPHORESIS; LIPOSOMES; NANOPARTICLES; PATENTS AS TOPIC; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; SKIN; SKIN ABSORPTION;

EID: 67650397156     PISSN: 18722113     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221109788452285     Document Type: Review

References (228)

1. Godin B, Touitou E. Transdermal skin delivery: Predictions for humans from in vivo, ex vivo and animal models. Adv Drug Deliv Rev 2007; 59: 1152-1161.
2. Barry BW. Drug delivery routes in skin: A novel approach. Adv Drug Deliv Rev 2002; 54 (Suppl 1): S31-S40.
3. Brown MB, Martin GP, Jones SA, Akomeah FK. Dermal and transdermal drug delivery systems: Current and future prospects. Drug Deliv 2006; 13: 175-187.
4. Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 2001; 14: 101-114.
5. Tiwary AK, Sapra B, Jain S. Innovations in transdermal drug delivery: Formulations and techniques. Recent Pat Drug Deliv Formul 2007; 1: 23-36.
6. Bogner RH, Wilkosz MF. Transdermal drug delivery part 2: Upcoming developments. US Pharmacist 2003; 28:05.
7. Santus GC, Baker RW. Transdermal enhancer patent literature. J Control Release 1993; 25: l-20.
8. Bach M, Lippold BC. Percutaneous penetration enhancement and its quantification. Eur J Pharm Biopharm 1998; 46:1-13.
9. Peck KD, Ghanem A-H, Higuchi WI. Hindered diffusion of polar molecules through and effective pore radii estimates of intact and ethanol treated human epidermal membrane. Pharm Res 1994; 11: 1306-1314.
10. Nair V, Pillai O, Poduri R, Panchagnula R. Transdermal iontophoresis. Part I: Basic principles and considerations. Methods Find Exp Clin Pharmacol 1999; 21:139-151.
11. Haak, R.P., Theeuwes, F., Gyory, J.R., Lattin, G.A.: US5464387 (1995).
12. Kost, J., Pliquett, U., Mitragotri, S.S., Langer, R.S., Weaver, J.C.: US20006041253 (2000).
13. Abramson HA, Gorin MH. Skin reactions IX. The electrophoretic demonstration of the patent force of the living human skin: Its relation to the charge of the skin. J Phys Chem 1940; 44: 1094-1102.
14. Cullander C. What are the pathways of iontophoretic current flow through mammalian skin? Adv Drug Deliv Rev 1992; 9: 119-135.
15. Jadoul A, Bouwstra J, Preat V. Effects of iontophoresis and electroporation on the stratum corneum: Review of the biophysical studies. Adv Drug Deliv Rev 1999; 35: 89-105.
16. Monteiro-Riviere NA, Inman AO, Riviere JE. Identification of the pathway of iontophoretic drug delivery: Light and ultrastructural studies using mercuric chloride in pigs. Pharm Res 1994; 11: 251-256.
17. Higuchi WI, Li SK, Gahnem AH, Zhu H, Song Y. Mechanistic aspects of iontophoresis in human epidermal membrane. J Control Rel 1999; 62:13-23.
18. Panchagnula R, Desu H, Jain A, Khandavilli S. Effect of lipid bilayer alteration on transdermal delivery of a high-molecular-weight and lipophilic drug: Studies with paclitaxel. J Pharm Sci 2004; 93: 2177-2183.
19. Powers, W.R., Sisun, H.: US4702732 (1987).
20. McNichols, L.A., Badzinski, J.D., Phipps, J.B., Lattin, G.A., Sorenson, P.D.: US4725263 (1988).
21. Chien, Y.W., Chen, L.H.: US5362308 (1994).
22. McNichols, L.A., Lattin, G.A.: US5047007 (1991).
23. Brange, J.J.V.: US5597796 (1997).
24. Okabe, K., Sunahori, S., Kyo, E.: US5894021 (1999).
25. Effenhauser, C.S.: US20006032073 (2000).
26. Allen, Jr L.V.: US20006119036 (2000).
27. Suzuki, Y., Iga, K., Matsumoto, Y.: US20016248349 (2001).
28. Weaver JC, Chizmadzhev Yu A. Theory of electroporation: A review. Bioelectrochem Bioenerg 1996; 41:135-160.
29. Vanbever R, Lecouturier N, Preat V. Transdermal delivery of metoprolol by electroporation. Pharm Res 1994; 11: 1657-1662.
30. Prausnitz MR. A practical assessment of transdermal drug delivery by skin electroporation. Adv Drug Deliv Rev 1999; 35: 61-76.
31. Lombry C, Dujardin N, Preat V. Transdermal delivery of macromolecules using skin electroporation. Pharm Res 2000; 17: 32-37.
32. Vanbever R, Preat V. In vivo Efficacy and safety of skin electroporation. Adv Drug Deliv Rev 1999; 35: 77-88.
33. Prausnitz MR, Bose VG, Langer R, Weaver JC. Electroporation of mammalian skin: A mechanism to enhance transdermal drug delivery. Proc Natl Acad Sci USA 1993; 90: 10504-10508.
34. Vanbever R, De Morre N, Preat V. Transdermal delivery of fentanyl by electroporation: II. Mechanisms involved in drug transport. Pharm Res 1996; 13: 1359-1365.
35. Vanbever R, Lecouturier N, Preat V. Transdermal delivery of metoprolol by electroporation. Pharm Res 1994; 11: 1657-1662.
36. Cruz MP, Eeckhoudt SL, Verbeeck RK, Preat V. Transdermal delivery of flurbiprofen in the rat by iontophoresis and electroporation. Pharm Res 1997; 14: 309.
37. Wang S, Kara M, Krishnan RR. Transdermal delivery of cyclosporin-A using electroporation. J Control Release 1998; 50: 61-70.
38. Prausnitz MR, Edelman ER, Gimm JA, Langer R, Weaver JC. Transdermal delivery of heparin by skin electroporation. Biol Technol 1995; 13: 1205-1209.
39. Zewert TE, Pliquett UF, Langer R, Weaver JC. Transdermal transport of DNA antisense oligonucleotides by electroporation. Biochem Biophys Res Commun 1995; 212: 286-292.
40. Zewert TE, Pliquett UF, Vanbever R, Langer R, Weaver JC. Creation of transdermal pathways for macromolecule transport by skin electroporation and a low toxicity, pathway-enlarging molecule. Bioelectrochem Bioenerg 1999; 49: 11- 20.
41. Zhang L, Li L, An ZL, Hoffman RM, Hofmann GA. in vivo Transdermal delivery of large molecules by pressuremediated electroincorporation and electroporation: A novel method for drug and gene therapy. Bioelectrochem Bioenerg 1997; 42: 283-292.
42. Tomov TC. Quantitative dependence of electroporation on the pulse parameters. Bioelectrochem Bioenerg 1995; 37: 101-107.
43. Weaver JC, Vaughan TE, Chizmadzhev YA. Theory of electrical creation of aqueous pathways across skin transport barriers. Adv Drug Deliv Rev 1999; 35: 21-39.
44. Weaver, J.C., Powell, K.T., Langer, Jr., Robert, S.: US5019034 (1991).
45. Hofmann, G.A.: US5273525 (1993).
46. Hofmann, G.A.: US5318514 (1994).
47. Zhang, L., Rabussay, D.P.: US6972013 (2005).
48. Fellinger K, Schmidt J. Klinik and therapies des chromischen gelenkreumatismus. Maudrich Vienna Austria 1954; 549-552.
49. Mitragotri S, Kost J. Low frequency sonophoresis: A review. Adv Drug Deliv Rev 2004; 56: 589-601.
50. Merino G, Kalia YN, Guy RH. Ultrasound-enhanced transdermal transport. J Pharm Sci 2003; 92: 1125-1137.
51. Bommannan D, Menon GK, Okuyama H, Elias PM, Guy RH. Sonophoresis: II. Examination of the mechanism(s) of ultrasound-enhanced transdermal drug delivery. Pharm Res 1992; 9: 1043-1047.
52. Mitragotri S, Blankschtein D, Langer R. Ultrasound-mediated transdermal protein delivery. Science 1995; 269: 850-853.
53. Tezel A, Sens A, Tuscherer J, Mitragotri S. Frequency dependence of sonophoresis. Pharm Res 2001; 18: 1694-1700.
54. Boucaud A, Garrigue MA, Machet L, Vaillant L, Patat F. Effect of sonication parameters on transdemral delivery of insulin to hairless rats. J Pharm Sci 2002; 91: 113-119.
55. Lavon I, Kost J. Ultrasound and transdermal drug delivery. Drug Discov Today 2004; 9: 670-676.
56. Kost, J., Levy, D., Langer, R.S.: US4767402 (1988).
57. Kost, J., Langer, R.S.: US4780212 (1988).
58. Shimada, J., Shapland, J.E.: US5267985 (1993).
59. Lipkovker, L.M.: US5421816 (1995).
60. Mitragotri, S.S., Blankschtein, D., Langer, R.S.: US5814599 (1998).
61. Mitragotri, S.S., Blankschtein, D. Langer, R.S.: US6002961 (1999).
62. Mitragotri, S.S., Blankschtein, D. Langer, R.S.: US20006018678 (2000).
63. Weimann, L., Childs, R.: US20056842641 (2005).
64. Weimann, L.J.: US20077232431 (2007).
65. Murthy SN, Hiremath SRR. Physical and chemical permeation enhancers in transdermal delivery of terbutaline sulphate. AAPS Pharm Sci Tech 2001; 2: 1-5.
66. Giammarusti, P.: US20046795727 (2004).
67. Ostrow, A.S.: US5983134 (1999).
68. Ostrow, A., Koops, G.-H., Tannenbaum, J.: US20036564093 (2003).
69. Godshall, N.A., Anderson, R.R.: US5879326 (1999).
70. Lee, H.B., Shin, B.C.: US5250023 (1993).
71. Henry S, McAllister D, Allen MG, Prausnitz MR. Microfabricated microneedles: A novel method to increase transdermal drug delivery. J Pharm Sci 1998; 87: 922-925.
72. Prausnitz MR. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev 2004; 56: 581-587.
73. McAllister DV, Wang PM, Davis SP, et al. Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: Fabrication methods and transport studies. Proc Natl Acad Sci USA 2003; 100:13755-13760.
74. Smart WH, Subramanian K. The Use of silicon microfabrication technology in painless blood glucose monitoring. Diab Tech Ther 2000; 2: 549-559.
75. Lee JW, Park JH, Prausnitz MR. Dissolving microneedles for transdermal drug delivery. Biomaterials 2008; 29: 2113-2124.
76. Lin W, Cormier M, Samiee A, et al. Transdermal delivery of antisense oligonucleotides with microprojection patch (Macroflux) technology. Pharm Res 2001; 18: 1789-1793.
77. Martanto W, Davis S, Holiday N, Wang J, Gill H, Prausnitz M. Transdermal delivery of insulin using microneedles in vivo. Proceedings of International Symposium on Controlled Release Bioactive Material 2003; p. 666.
78. Cormier M, Daddona PE. Macroflux technology for transdermal delivery of therapeutic proteins and vaccines. In: Rathbone MJ, Hadgraft J, Roberts S, Eds. Modified-release drug delivery technology. Marcel Dekker, New York 2003; 589-598.
79. Matriano JA, Cormier M, Johnson J, Young WA, Buttery M, Nyam K. Macroflux (R) microprojection array patch technology: A new and efficient approach for intracutaneous immunization. Pharm Res 2002; 19: 63-70.
80. Miyano T, Tobinaga Y, Kanno T, Matsuzaki Y, Takeda H, Wakui M. Sugar micro needles as transdermic drug delivery system. Biomed Microdevices 2005; 7:185-188.
81. Park JH, Allen MG, Prausnitz MR. Polymer microneedles for controlled release drug delivery. Pharm Res 2006; 23:1008-1019.
82. Gill HS, Prausnitz MR. Coated microneedles for transdermal delivery. J Controll Release 2007; 117: 227-237.
83. Cormier, M.J.N., Nat, A.S., Neukermans, A.P., Block, B.: US20016230051 (2001).
84. Eppstein, J.A.: US20036527716 (2003).
85. Ginaven, R.O., Facciotti, D.: US5457041 (1995).
86. Cormier, M.J.N., Theeuwes, F.: US20036537264 (2003).
87. Weaver, J.C.: US5389069 (1995).
88. King, A.D., Walters, R.E.: US20036603998 (2003).
89. Rosenberg, Z.B.: US20036623457 (2003).
90. Gertsek, M., Wilkinson, B.M., Pettis, R.J.: US20036656147 (2003).
91. Prausnitz, M.R., Allen, M.G., Henry, S., McAllister, D.V., Ackley, D.E., Jackson, T.: US20046743211 (2004).
92. Cho, S.T.: US20056980855 (2005).
93. Wilkinson, B.M., Hwang, C.G.: US20067047070 (2006).
94. Gartstein, V., Sherman, F.F.: US20067108681 (2006).
95. Angel, A.B., Hunter, I.W., Hansen, P.: US20067066922 (2006).
96. Angel, A.B., Hunter, I.W.: US20087364568 (2008).
97. Cormier, M.J.N., Neukermans, A.P., Block, B., Theeuwes, F.T., Amkraut, A.A.: US20077184826 (2007).
98. Elsayed MMA, Abdullah OY, Naggar VF, Khalafallah NM. Lipid vesicles for skin delivery of drugs: Reviewing three decades of research. Int J Pharm 2007; 332: 1-16.
99. Schreier H, Bouwstra J. Liposomes and niosomes as topical drug carriers: Dermal and transdermal drug delivery. J Controll Release 1994; 30: 1-15.
100. Mehta, R.C., Hardee, G.E., Cook, P.D., Ecker, D.J., Tsai, Y.J., Templin, M.V.: US20056841539 (2005).
101. Weiner N, Martin F, Riaz M. Liposomes as a drug delivery system. Drug Dev Ind Pharm 1989; 15: 1523-1554.
102. Liu J, Hu G. Advances in studies of phospholipids as carriers in skin topical application. J Nanj Medical Univ 2007; 21: 349-353.
103. Mezei M, Gulasekharam V. Liposomes- a selective drug delivery system for the topical route of administration. Lotion dosage form. Life Sci 1980; 26: 1473-1477.
104. Mezei M, Gulasekharam V. Liposomes- a selective drug delivery system for the topical route of administration: Gel dosage form. J Pharm Pharmacol 1982; 34: 473-474.
105. Brucks, R.M., Duvel, L.A.: US5720948 (1998).
106. Kirjavainen M, Urtti A, Jaaskelainen I. Interaction of liposomes with human skin in vitro- the influence of lipid composition and structure. Biochim Biophys Acta 1996; 1304: 179-189.
107. Kirjavainen M, Urtti A, Valjakka-Koskelab R, Kiesvaarab J, Monkkonen J. Liposome-skin interactions and their effects on the skin permeation of drugs. Eur J Pharm Sci 1999; 7: 279-286
108. Hofland HEJ, Bouwstra JA, Spies F. Interactions between non-ionic surfactant vesicles and human stratum corneum in vitro. J Liposome Res 1995; 5: 241-263.
109. Wheatley, M.A., Langer, R.S., Eisen, H.N.: US4921757 (1990).
110. Herslof, B., Nicklasson, AG.M.: US5665379 (1997).
111. Thierry, A.R.: US20006110490 (2000).
112. Unger, E.C., Fritz, T.A., Matsunaga, T., Ramaswami, V., Yellowhair, D., Wu, G.: US5770222 (1998).
113. Unger, E.C.: US20006143276 (2000).
114. Sanders, B., Kline, K., Lawson, K. A., Knight, V. J., Menchaca, M. S., Wellen, C.W.: US20030236301A1 (2003)
115. Mezei, M., Gaal, J., Szekacs, G., Szebeni, G., Marmarosi, K., Magyar, K., Lengyel, J., Szatmari, I., Turi, A.: US5888536 (1999).
116. Uster, P.S., Morano, J.K., Martin, F.J.: US5064655 (1991).
117. Foldvari, M.: US5718914 (1998).
118. Alving, C.R., Glenn, G.M.: US5910306 (1999).
119. Bouwstra, J.A.: US5830499 (1998).
120. Cevc G. Transfersomes: Innovative transdermal drug carriers. In: Eds. Rathbone MJ, Hadgraft J, Robert MS. Modified Release Drug Delivery Technology 126: pp. 533-545.
121. Honeywell-Nguyen PL, Bouwstra JA. Vesicles as a tool for transdermal and dermal delivery. Drug Discov Today: Technol 2005; 2: 67-74.
122. Cevc G, Schatzlein A, Richardsen H. Ultradeformable lipid vesicles can penetrate the skin and other semi-permeable barriers unfragmented. Evidence from double label CLSM experiments and direct size measurements. Biochim Biophys Acta 2002; 1564: 21-30.
123. Van den Bergh BA, Vroom J, Gerritsen H, Junginger HE, Bouwstra JA. Interactions of elastic and rigid vesicles with human skin in vitro: Electron microscopy and two-photon excitation microscopy. Biochim Biophys Acta 1999; 1461: 155-173.
124. Planas ME, Gonzalez P, Rodriguez L, Sanchez S, Cevc G. Noninvasive percutaneous induction of topical analgesia by a new type of drug carrier, and prolongation of local pain insensitivity by anesthetic liposomes. Anesth Analg 1992; 75: 615-621.
125. Guo J, Ping Q, Sun G, Jiao C. Lecithin vesicular carriers for transdermal delivery of cyclosporin A. Int J Pharm 2000; 194: 201-207.
126. Cevc G, Blume G. New, highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers, transfersomes. Biochim Biophys Acta 2001; 1514: 191-205.
127. Garg M, Mishra D, Agashe H, Jain NK. Ethinylestradiol loaded ultraflexible liposomes:Pharmacokinetics and pharmacodynamics. J Pharm Pharmacol 2006; 58: 459-468.
128. Cevc G. Transdermal drug delivery of insulin with ultradeformable carriers. Clin Pharmacokinet 2003; 42: 461-474.
129. Cevc, G.: US20077175850 (2007).
130. Cevc, G.: US20006165500 (2000).
131. Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes-novel vesicular carriers for enhanced delivery: Characterization and skin penetration properties. J Control Release 2000; 65: 403-418.
132. Touitou, E.: US5540934 (1996).
133. Dubey V, Mishra D, Dutta T, Nahar M, Saraf DK, Jain NK. Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. J Controll Release 2007; 123: 148-154.
134. Elsayed MMA, Abdallah OY, Naggar VF, Khalafallah NM. Deformable liposomes and ethosomes: Mechanism of enhanced skin delivery. Int J Pharm 2006; 322: 60-66.
135. Touitou E, Godin B, Weiss C. Enhanced delivery of drugs into and across the skin by ethosomal carriers. Drug Dev Res 2000; 50: 406-415.
136. Modi, P.: US20060182766A1 (2006).
137. Modi, P.: US20060182794 A1 (2006).
138. Hoar T P, Schulman J H. Transparent water in oil dispersions: The oleopathic hydro-micelle. Nature 1943; 152: 102-103.
139. Sintov AC, Shaprio L. New microemulsions vehicle facilitates percutaneous penetration invitro and cutaneous drug bioavailability in vivo. J Controll Release 2004; 95: 173-183.
140. Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar R K, Ali M. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Sci 2007; 66: 227-243.
141. Eccleston J. Microemulsions. In: Encyclopedia of pharmaceutical technology Marcel Dekker New York 1994; Vol. 9: pp. 375-421.
142. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 2000; 45: 89-121.
143. Thacrodi D, Panduranga RK. Transdermal absorption of nifedipine from microemulsions of lipophilic skin penetration enhancers. Int J Pharm 1994; 111: 235-240.
144. Baroli B, Lopez-Quintela M, Begon M, Delgado-Charrod, Fadda AM, Blanco-Mendez J. Microemulsions for topical delivery of 8-methoxsalen. J Controll Release 2000; 69: 209-218.
145. Kreilgaard M, Pedersen EJ, Jaroszewski JW. NMR characterisation and transdermal drug delivery potential of microemulsion systems. J Controll Release 2000; 69: 421-433.
146. Alvarez-Figueroa MS, Blasnco-Mendez J. Transdermal delivery of methotrexate: Iontophoretic delivery from hydrogels and passive delivery from microemulsions. Int J Pharm 2001; 215: 57-65.
147. Rhee YS, Choi JG, Park ES, Chi SC. Transdermal delivery of ketoprofen using microemulsions. Int J Pharm 2001; 228: 161-170.
148. Peltola S, Savolainen PS, Kiesvaara J, Suhonen TM, Urtti A. Microemulsions for topical delivery of estradiol. Int J Pharm 2003; 254: 99-107.
149. Chen H, Chang X, Weng T, et al. A study of microemulsion systems for transdermal delivery of triptolide. J Controll Release 2004; 98: 427- 436.
150. Gupta RR, Jain SK, Varshney M. AOT water-in-oil microemulsions as a penetration enhancer in transdermal drug delivery of 5-fluorouracil. Colloids Surf B Biointerfaces 2005; 41: 25-32.
151. Djordjevic L, Primorac M, Stupar M. in vitro Release of diclofenac diethylamine from caprylocaproyl macrogolglycerides based microemulsions. Int J Pharm 2005; 296: 73-79.
152. Kogan A, Garti N. Microemulsions as transdermal drug delivery vehicles. Adv Colloid Interface Sci 2006; 123-126: 369-385.
153. Dreher F, Walde P, Walther P, Wehrli E. Interaction of a lecithin microemulsion gel with human stratum corneum and its effect on transdermal transport. J Controll Release 1997; 45: 131-140.
154. Trotta M, Morel S, Gasco M R. Effect of oil phase composition on the skin permeation of felodipine from o/w microemulsions. Pharmazie 1997; 52: 50-53.
155. Schmalfuss U, Neubert R, Wohlrab W. Modification of drug penetration into human skin using microemulsions. J Controll Release 1997; 46: 279-285.
156. Huang YB, Lin YH, Lu TM, Wang RJ, Tsai YH, Wu PC. Transdermal delivery of capsaicin derivative-sodium nonivamide acetate using microemulsions as vehicles. Int J Pharm 2008; 349: 206-211.
157. Muller, B.W.W., Franzky, H-J.: US4719239 (1988).
158. Bauer, K., Neuber, C., Schmid, A., Volker, K.M.: US20026426078 (2002).
159. Patel, M.V., Chen, F.-J.: US20026451339 (2002).
160. Roessler, B.J., Baker, J.R., Weiner, N.D., Chandrasekharan, R., Wu, H. L.: US20020155084A1 (2002).
161. Baker, J.R., Hamouda, T.: US20030194412 (2003).
162. Cowsert, L.M.: US5951455 (1999).
163. Teng, C-L., Cook, P.D., Tillman, L., Hardee, G.E.., Ecker, D.J., Manoharan, M.: US20046747014 (2004).
164. Baker, J.R., Hamouda, T.: US200820087314624 (2008).
165. Simonnet, J.-T., Sonneville, O., Legret, S.: US20026413527 (2002).
166. Simonnet, J.-T., Sonneville, O., Legret, S.: US20016274150 (2001).
167. Owen, A.J., Yiv, S.H., Sarkahian, A.B.: US5688761 (1997).
168. Kreckel, K.W., Zerbe, H-G.: US5244677 (1993).
169. Muller RH, Karsten M, Sven G. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 2000; 50: 161-177.
170. Maia CS, Mehnert W, Schaller M, et al. Drug targeting by solid lipid nanoparticles for dermal use. J Drug Target 2002; 10: 489-495.
171. Herzog, B.: US20067147841 (2006).
172. Wolfgang M, Karsten M. Solid lipid nanoparticles production, characterization and applications. Adv Drug Deliv Rev 2001; 47: 165-196.
173. Westesen, K.: US5885486 (1999).
174. Gasco, M.R.: US20046685960B1 (2004).
175. Muller, R.H., Olbrich, C.: US20046770299 (2004).
176. Jain SK, Chourasia MK, Masuriha R, et al. Solid lipid nanoparticles bearing flurbiprofen for transdermal delivery. Drug Deliv 2005; 12: 207-215.
177. Shah KA, Date AA, Joshi MD, Patravale VB. Solid lipid nanoparticles (SLN) of tretinoin: Potential in topical delivery. Int J Pharm 2007; 345: 163-171.
178. Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002; 54: S131-S155.
179. Constantinides, P., Patil, R.T., Liang, L.: US20060078618 (2006).
180. DeVringer, T.: US5904932 (1999).
181. Chen, T., Vargeese, C., Vagle, K., Wang, W., Zhang, Y.: US20087404969 (2008).
182. Westesen, K., Siekmann, B.: US20016207178 (2001).
183. Muller, R.H., Olbrich, C.: US20046770299 (2004).
184. Schwarz, J., Weisspapir, M.: US20060222716 (2006).
185. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev 2004; 56: 603- 618.
186. Walker RB, Smith EW. The role of percutaneous penetration enhancers. Adv Drug Deliv Rev 1996; 18: 295-301.
187. Aqil M, Ahad A, Sultana Y, Ali A. Status of terpenes as skin penetration enhancers. Drug Discov Today 2007; 12: 1061-1067.
188. Williams AC, Barry BW. Terpenes and the lipid-protein-partioning theory of skin penetration enhancement. Pharm Res 1991; 8:17-24.
189. Barry BW. LPP theory of skin penetration enhancement. J Controll Release 1991; 15: 237-248.
190. Govil, S.K., Rudnic, E.M., Sterner, D.G.: US5262165 (1993).
191. Wick, S.M.: US4751087 (1988).
192. Barnhart, S.D., Mariani, E.P.: US5762952 (1998).
193. Bodor, N., Loftsson, T.: US4885174 (1989).
194. Bodor, N., Loftsson, T.: US4764381 (1988).
195. Cooper, E.R.: US4537776 (1985).
196. Cooper, E.R: US4557934 (1985).
197. Rajadhyaksha, V.J.: US4405616 (1983).
198. Moore, C.L., Nelson, G.R., Wick, S.M., Zerbe, H-G.: US5223261 (1993).
199. Hsu, T-M., Jacobson, E.C., LoBello, R.C., Luo, E.C.: US20046835392 (2004).
200. Carrara, D., Porto, G., Rodriguez, J.: US20077214381 (2007).
201. Ebert, C.D., Sanders, S.W.: US20077179483 (2007).
202. Choi, Y.K., Yu, H.S., Yoon, H.J., Kim, H.C.: US20046791003 (2004).
203. Luo, E.C., Jacobson, E.C., Hsu, T.-M.: US20036565879 (2003).
204. Hsu, T-M., Macy, R., Luo, E.C.: US200476719997 (2004).
205. Hsu, T-M., Macy, R., Luo, E.C.: US20077244447 (2007).
206. Hsu, T-M., Macy, R., Luo, E.C.: US20036645520 (2003).
207. Hsu, T-M., Macy, R., Luo, E.C.: US20036602912 (2003).
208. Luo, E.C., Jacobson, E.C., Hsu, T-M.: US20036586000 (2003).
209. Luo, E.C., Gricenko, N.T., Hsu, T-M.: US20046673363 (2004).
210. Patrick, J.:US5496827 (1996).
211. Gueret, J-l., Lebreton, F., Contamin, J-C.: US5100672 (1992).
212. Haralambopoulos, C., Ryan, P.: US5958447 (1999).
213. Bracher, D.: US5989585 (1999).
214. Zeltman, J.D.: US20080233180A1 (2008).
215. Francoeur, M.L., Potts, R.O.: US5023085 (1991).
216. Huntington, J.A., Cormier, M.: US5736580 (1998).
217. Eppstein, J.A., Eppstein, D.A.: US5445611 (1995).
218. Giammarusti, P.: US20046795727 (2004).
219. Ben-Amoz, D.: US4866050 (1989).
220. Henley, J.L.: US5415629 (1995).
221. Rowe, S., Kost, J., Mitragotri, S.S., Pishko, M., Davis, M.: US20016234990 (2001).
222. Mitragotri, S.S., Blankschtein, D., Langer, R.S.: US5814599 (1998).
223. Eppstein, J.A.: US20036527716 (2003).
224. Bommannan, D., Okuyama, H., Guy, R.H., Stauffer, P., Flynn, G.L. US5115805 (1992).
225. Eppstein, J.A., Eppstein, D.A., Kost, J, Langer, R.S.: US5458140 (1995).
226. Eppstein, J.A.: US5722397 (1998).
227. Seward, K.P.: US20067127284 (2006).
228. Kwiatkowski, M.: US20087345163 (2008).